X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13432) 13432
Publication (645) 645
Book Review (98) 98
Book / eBook (55) 55
Magazine Article (45) 45
Book Chapter (27) 27
Conference Proceeding (10) 10
Dissertation (10) 10
Newspaper Article (7) 7
Newsletter (6) 6
Trade Publication Article (3) 3
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (13138) 13138
humans (13070) 13070
adult (5481) 5481
middle aged (5120) 5120
uterine cervical neoplasms - drug therapy (4715) 4715
index medicus (4034) 4034
oncology (4018) 4018
uterine neoplasms - drug therapy (3484) 3484
aged (3008) 3008
uterine cervical neoplasms - pathology (2891) 2891
obstetrics & gynecology (2749) 2749
cervical cancer (2710) 2710
cancer (2606) 2606
antineoplastic combined chemotherapy protocols - therapeutic use (1895) 1895
chemotherapy (1767) 1767
uterine cervical neoplasms - radiotherapy (1669) 1669
pregnancy (1654) 1654
uterine neoplasms - pathology (1476) 1476
treatment outcome (1442) 1442
combined modality therapy (1418) 1418
animals (1389) 1389
neoplasm staging (1320) 1320
antineoplastic agents - therapeutic use (1249) 1249
carcinoma, squamous cell - drug therapy (1200) 1200
carcinoma (1174) 1174
cisplatin - administration & dosage (1108) 1108
hysterectomy (1100) 1100
care and treatment (1086) 1086
radiotherapy (1050) 1050
prognosis (1035) 1035
uterine neoplasms - surgery (1014) 1014
cisplatin (1009) 1009
cell line, tumor (977) 977
male (964) 964
uterine cervical neoplasms - therapy (928) 928
uterine cervical neoplasms - surgery (926) 926
uterine cervical neoplasms - metabolism (923) 923
apoptosis (918) 918
uterine cervix (890) 890
mice (883) 883
hela cells (869) 869
retrospective studies (869) 869
leiomyoma - drug therapy (852) 852
adenocarcinoma - drug therapy (840) 840
health aspects (781) 781
research (759) 759
apoptosis - drug effects (749) 749
tumors (748) 748
follow-up studies (729) 729
women (716) 716
chemotherapy, adjuvant (698) 698
risk factors (697) 697
therapy (689) 689
time factors (676) 676
expression (675) 675
carcinoma, squamous cell - pathology (642) 642
uterine cervical neoplasms - genetics (630) 630
aged, 80 and over (627) 627
gynecologic-oncology-group (627) 627
adolescent (609) 609
analysis (608) 608
surgery (608) 608
obstetrics and gynecology (603) 603
antineoplastic agents - pharmacology (592) 592
uterine cervical neoplasms - mortality (587) 587
breast neoplasms - drug therapy (586) 586
hematology, oncology and palliative medicine (579) 579
squamous-cell carcinoma (565) 565
prospective studies (563) 563
dose-response relationship, drug (559) 559
drug administration schedule (556) 556
ovarian neoplasms - drug therapy (555) 555
cell proliferation - drug effects (550) 550
neoplasm recurrence, local - drug therapy (546) 546
antineoplastic combined chemotherapy protocols - adverse effects (539) 539
antineoplastic agents - administration & dosage (533) 533
radiation-therapy (532) 532
uterine cervical neoplasms - virology (528) 528
disease-free survival (525) 525
uterus (521) 521
radiology, nuclear medicine & medical imaging (515) 515
human papillomavirus (512) 512
drug therapy (508) 508
uterine neoplasms - therapy (507) 507
survival rate (501) 501
pharmacology & pharmacy (498) 498
neoplasm metastasis (491) 491
cisplatin - therapeutic use (490) 490
carcinoma, squamous cell - radiotherapy (476) 476
uterine cervical neoplasms - diagnosis (472) 472
risk (462) 462
metastasis (461) 461
drug therapy, combination (459) 459
choriocarcinoma - drug therapy (455) 455
survival (453) 453
uterine neoplasms - diagnosis (451) 451
cervix (439) 439
adenocarcinoma - pathology (430) 430
tumor cells, cultured (421) 421
diagnosis (412) 412
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11430) 11430
Japanese (516) 516
German (389) 389
Russian (294) 294
French (279) 279
Chinese (189) 189
Italian (140) 140
Spanish (83) 83
Polish (59) 59
Bulgarian (43) 43
Czech (38) 38
Hungarian (18) 18
Ukrainian (17) 17
Dutch (15) 15
Portuguese (14) 14
Danish (12) 12
Swedish (9) 9
Hebrew (8) 8
Finnish (6) 6
Norwegian (6) 6
Romanian (6) 6
Serbian (6) 6
Korean (5) 5
Slovak (5) 5
Bosnian (2) 2
Arabic (1) 1
Croatian (1) 1
Lithuanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 06/2017, Volume 23, Issue 6, pp. 664 - 673
Neuroendocrine (NE) cancers are a diverse group of neoplasms typically diagnosed and treated on the basis of their site of origin. This Perspective focuses on... 
MOLECULAR CHARACTERIZATION | MEDICINE, RESEARCH & EXPERIMENTAL | PANCREATIC ENDOCRINE NEOPLASMS | TRANSGENIC MOUSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTIANDROGEN RESISTANCE | CONDITIONAL MOUSE MODEL | AURORA KINASE | METASTATIC PROSTATE-CANCER | T-ANTIGEN | CELL BIOLOGY | CELL LUNG-CANCER | N-MYC | Lung Neoplasms - drug therapy | Colonic Neoplasms - genetics | Carcinoma, Small Cell - genetics | Colonic Neoplasms - drug therapy | Epigenesis, Genetic | Humans | Male | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Tumor Suppressor Protein p53 - genetics | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Prostatic Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Female | Cell Differentiation | Retinoblastoma Binding Proteins - genetics | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Triazoles - therapeutic use | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Neuroendocrine - drug therapy | Carcinoma, Small Cell - drug therapy | Carcinogenesis - genetics | Head and Neck Neoplasms - drug therapy | Carcinoma, Neuroendocrine - genetics | Uterine Cervical Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Uterine Cervical Neoplasms - genetics | Disease Progression | Azepines - therapeutic use | Neuroendocrine Tumors - genetics | Proto-Oncogene Proteins c-met - genetics | Cell Lineage | Cell Plasticity - genetics | Esophageal Neoplasms - genetics | Pyrimidines - therapeutic use | Neuroendocrine Tumors - drug therapy | Head and Neck Neoplasms - genetics | Proto-Oncogene Proteins c-myc - genetics | Ubiquitin-Protein Ligases - genetics | Benzodiazepines - therapeutic use | Esophageal Neoplasms - drug therapy | Proteins | Research | Health aspects | Carcinogenesis | Gastrin
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, p. e0145754
Background High-grade serous ovarian and endometrial cancers are the most lethal female reproductive tract malignancies worldwide. In part, failure to treat... 
CA-125 | MULTIDISCIPLINARY SCIENCES | EPITHELIAL OVARIAN-CANCER | Endometrial Neoplasms - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Genital Neoplasms, Female - drug therapy | DNA, Neoplasm - blood | Endometrial Neoplasms - genetics | Adult | Female | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Genital Neoplasms, Female - genetics | CA-125 Antigen - blood | Ovarian Neoplasms - blood | Genital Neoplasms, Female - blood | Mutation - genetics | Breast Neoplasms - drug therapy | Biomarkers, Tumor - blood | Genital Neoplasms, Female - mortality | Exome - genetics | Breast Neoplasms - genetics | Breast Neoplasms - blood | Breast Neoplasms - mortality | Endometrial Neoplasms - drug therapy | Neoplasm Recurrence, Local - genetics | Aged | Biomarkers, Tumor - genetics | DNA, Neoplasm - genetics | Endometrial Neoplasms - blood | Physiological aspects | Prognosis | Biological markers | Genital cancer | Tumors | Plasma | Scanning | Ovarian carcinoma | Medical services | Fallopian tube | Cancer therapies | Ovarian cancer | Gene sequencing | Computed tomography | Surgery | Quality | Imaging | Bioindicators | Endometrium | Deoxyribonucleic acid--DNA | DNA probes | Gynecology | Breast cancer | Patients | Survival | Obstetrics | Medicine | Lead time | Chemotherapy | Surveillance | Womens health | Biomarkers | Diagnostic systems | Mutation | Reproductive system | Uterine cancer | Peritoneum | Cancer | Deoxyribonucleic acid | DNA
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 6, pp. 770 - 780
Abstract Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently approved for breast, gastric, and gastroesophageal cancers... 
Hematology, Oncology and Palliative Medicine | Human epidermal growth factor 2 | Pertuzumab | Afatinib | Target therapy | Lapatinib | Ado-trastuzumab emtansine | Trastuzumab | Cancer | GYNECOLOGIC-ONCOLOGY-GROUP | IN-SITU HYBRIDIZATION | UROTHELIAL BLADDER-CANCER | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | SALIVARY DUCT CARCINOMA | ONCOLOGY | METASTATIC BREAST-CANCER | AFATINIB BIBW 2992 | GENE AMPLIFICATION | Neoplasms - metabolism | Up-Regulation | Receptor, ErbB-2 - genetics | Humans | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Uterine Cervical Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Maytansine - pharmacology | Breast Neoplasms - metabolism | Peritoneal Neoplasms - drug therapy | Uterine Cervical Neoplasms - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Adult | Female | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Peritoneal Neoplasms - secondary | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Uterine Cervical Neoplasms - drug therapy | Clinical Trials as Topic | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Animals | Gene Amplification | Quinazolines - therapeutic use | Peritoneal Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacology | Mutation | Quinazolines - pharmacology | Care and treatment | Biological products | Epidermal growth factor | Lung cancer, Non-small cell | Health aspects
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 11/2017, Volume 99, Issue 4, pp. 1039 - 1047
Journal Article
Cancer Letters, ISSN 0304-3835, 2007, Volume 251, Issue 1, pp. 132 - 145
Abstract Betulinic acid (BA) is a widely available plant-derived triterpene with reported activity against cancer cells of neuroectodermal origin and... 
Hematology, Oncology and Palliative Medicine | Chemotherapy | Lung cancer | Betulinic acid | Colorectal cancer | Breast cancer | Prostate cancer | Cervical cancer | Apoptosis | ACTIVATION | colorectal cancer | INDUCED APOPTOSIS | breast cancer | apoptosis | TUMOR-CELLS | betulinic acid | IDENTIFICATION | cervical cancer | chemotherapy | CYTOTOXIC ACTIVITY | lung cancer | prostate cancer | ONCOLOGY | HUMAN-MELANOMA CELLS | SERINE-PROTEASE | INDUCED DEATH | INHIBITOR | DERIVATIVES | Neoplasms - metabolism | Lung Neoplasms - drug therapy | Prostatic Neoplasms - metabolism | Triterpenes - pharmacology | Apoptosis - drug effects | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Male | Uterine Cervical Neoplasms - pathology | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Uterine Cervical Neoplasms - metabolism | Colorectal Neoplasms - drug therapy | Female | Colorectal Neoplasms - metabolism | Prostatic Neoplasms - drug therapy | Cell Survival - drug effects | Prostatic Neoplasms - pathology | Jurkat Cells | Cells, Cultured | Uterine Cervical Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Blotting, Western | Neoplasms - drug therapy | Poly(ADP-ribose) Polymerases - metabolism | Breast Neoplasms - pathology | Cell Line, Tumor | Antineoplastic Agents, Phytogenic - pharmacology | Colorectal Neoplasms - pathology | Neoplasms - pathology | Cancer | Cell culture | Toxicity | Melanoma | Oncology | Cytotoxicity | Studies | Pathology | Acids | Rodents | Human immunodeficiency virus--HIV | Tumors
Journal Article
Cancer research, ISSN 0008-5472, 2013, Volume 73, Issue 8, pp. 2480 - 2492
Current therapy of gynecologic malignancies consists of platinum-containing chemotherapy. Resistance to therapy is associated with increased levels of... 
CELL LUNG-CANCER | RECURRENT CERVICAL-CANCER | CYCLOOXYGENASE-2 COX-2 | ONCOLOGY | CISPLATIN-DNA-ADDUCTS | INHIBITORY FACTOR | EXPRESSION | EPITHELIAL OVARIAN-CANCER | ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY | T-CELLS | SIGNAL TRANSDUCER | Antigen-Presenting Cells - cytology | Dinoprostone - biosynthesis | Monocytes - cytology | Dendritic Cells - immunology | Humans | STAT Transcription Factors - metabolism | Culture Media, Conditioned - pharmacology | NF-kappa B - metabolism | Antineoplastic Agents - therapeutic use | Monocytes - immunology | Receptors, Interleukin-6 - antagonists & inhibitors | Carboplatin - therapeutic use | Uterine Cervical Neoplasms - metabolism | Dendritic Cells - drug effects | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Macrophages - immunology | Cell Survival - drug effects | Antigen-Presenting Cells - drug effects | Uterine Cervical Neoplasms - immunology | Uterine Cervical Neoplasms - drug therapy | Cisplatin - pharmacology | Macrophages - cytology | Antigen-Presenting Cells - immunology | Neoplasms - drug therapy | Monocytes - drug effects | Tumor Microenvironment - immunology | Cisplatin - therapeutic use | Signal Transduction - drug effects | Cell Differentiation - drug effects | Neoplasms - immunology | Cell Line, Tumor | Interleukin-6 - biosynthesis | Macrophages - drug effects | Dendritic Cells - cytology | DNA Damage | Carboplatin - pharmacology | Ovarian Neoplasms - immunology | Receptors, Interleukin-6 - metabolism
Journal Article
Immunity, ISSN 1074-7613, 02/2017, Volume 46, Issue 2, pp. 197 - 204
Journal Article
Cancer Research, ISSN 0008-5472, 09/2017, Volume 77, Issue 18, pp. 5039 - 5053
Cancer immunoediting drives the adaptation of tumor cells to host immune surveillance. Immunoediting driven by antigen (Ag)-specific T cells enriches NANOG... 
UBIQUITINATION | HETEROGENEITY | LUNG-CANCER | ACTIVATION | REPRESSION | ONCOLOGY | MCL-1 | DRUG-RESISTANCE | LARGE GENE LISTS | INHIBITOR | PLASTICITY | Cell Proliferation | Prognosis | Breast Neoplasms - immunology | Neoplastic Stem Cells - drug effects | Drug Resistance, Multiple - drug effects | Epigenesis, Genetic | Humans | Transcriptional Activation | Neoplastic Stem Cells - immunology | Uterine Cervical Neoplasms - pathology | Biomarkers, Tumor | Breast Neoplasms - metabolism | Neoplastic Stem Cells - metabolism | Uterine Cervical Neoplasms - metabolism | Neoplastic Stem Cells - pathology | Female | Acetylation | Tumor Cells, Cultured | Histone Deacetylase 1 - genetics | Drug Resistance, Multiple - immunology | Nanog Homeobox Protein - genetics | Uterine Cervical Neoplasms - immunology | Uterine Cervical Neoplasms - drug therapy | Combined Modality Therapy | Drug Resistance, Neoplasm - immunology | Mice, SCID | Breast Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - pathology | Mice, Inbred NOD | Mice | Histones - metabolism | Neoplasm Staging | Nanog Homeobox Protein - metabolism | Apoptosis | Drug Resistance, Neoplasm - drug effects | Histone Deacetylase 1 - metabolism | Histone deacetylase | Tumor cells | Immunomodulation | Multidrug resistance | Immunosurveillance | Lymphocytes T | Drug resistance | Mcl-1 protein | Modulators | Genotype & phenotype | Lymphocytes | Immunotherapy | Epigenetics | Histone H3 | Cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 68, pp. 1 - 10
Abstract Purpose We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | MEK inhibitor | Phase I | Optimal biological dose | Pharmacokinetics | BRAF-MUTATED MELANOMA | MULTICENTER | SELUMETINIB PLUS DOCETAXEL | SAFETY | TRAMETINIB | CELL LUNG-CANCER | TRIAL | DOSE-ESCALATION | ONCOLOGY | DOUBLE-BLIND | AZD6244 ARRY-142886 | Lung Neoplasms - drug therapy | Pancreatic Neoplasms - metabolism | Nausea - chemically induced | Allosteric Regulation | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Fatigue - chemically induced | Ribosomal Protein S6 Kinases, 70-kDa - drug effects | Protein Kinase Inhibitors - adverse effects | Colorectal Neoplasms - drug therapy | Chromatography, Liquid | Proto-Oncogene Proteins c-akt - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Bile Duct Neoplasms - metabolism | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Administration, Oral | Carcinoma, Non-Small-Cell Lung - metabolism | Neoplasms - drug therapy | Maximum Tolerated Dose | Mesothelioma - metabolism | Mitogen-Activated Protein Kinase 3 - metabolism | Anorexia - chemically induced | Glycogen Synthase Kinase 3 beta - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Neoplasms - metabolism | Phosphoproteins - drug effects | Mitogen-Activated Protein Kinase 1 - drug effects | Cholangiocarcinoma - metabolism | Chromatography, High Pressure Liquid | Diarrhea - chemically induced | Mitogen-Activated Protein Kinase 3 - drug effects | Pancreatic Neoplasms - drug therapy | Tandem Mass Spectrometry | Uterine Cervical Neoplasms - metabolism | Esophageal Neoplasms - metabolism | Adult | Female | Colorectal Neoplasms - metabolism | Bile Duct Neoplasms - drug therapy | Drug Eruptions - etiology | Abdominal Pain - chemically induced | Uterine Cervical Neoplasms - drug therapy | Glycogen Synthase Kinase 3 beta - metabolism | Mesothelioma - drug therapy | Cholangiocarcinoma - drug therapy | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Esophageal Neoplasms - drug therapy | Proto-Oncogene Proteins c-akt - drug effects | Care and treatment | Protein kinases | Mitogens | Cells | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 5, pp. 421 - 432
Journal Article